Search

Your search keyword '"Fingerle-Rowson, Günter"' showing total 6 results
Start Over Author "Fingerle-Rowson, Günter" Publisher american society of clinical oncology
6 results on '"Fingerle-Rowson, Günter"'

1. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Author

Cheson, Bruce D., Chua, Neil, Mayer, Jiri, Dueck, Greg, Trněný, Marek, Bouabdallah, Kamal, Fowler, Nathan, Delwail, Vincent, Press, Oliver, Salles, Gilles, Gribben, John G., Lennard, Anne, Lugtenburg, Pieternella J., Fingerle-Rowson, Günter, Mattiello, Federico, Knapp, Andrea, Sehn, Laurie H., Trněný, Marek, and Fingerle-Rowson, Günter

Published
2018
Full Text
View/download PDF

2. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Author

Hiddemann, Wolfgang, Barbui, Anna Maria, Canales, Miguel A., Cannell, Paul K., Collins, Graham P., Dürig, Jan, Forstpointner, Roswitha, Herold, Michael, Hertzberg, Mark, Klanova, Magdalena, Radford, John, Seymour, John F., Tobinai, Kensei, Trotman, Judith, Burciu, Alis, Fingerle-Rowson, Günter, Wolbers, Marcel, Nielsen, Tina, Marcus, Robert E., and Dürig, Jan

Published
2018
Full Text
View/download PDF

3. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

Author

Vitolo, Umberto, Trnĕný, Marek, Belada, David, Burke, John M., Carella, Angelo Michele, Chua, Neil, Abrisqueta, Pau, Demeter, Judit, Flinn, Ian, Xiaonan Hong, Won Seog Kim, Pinto, Antonio, Yuan-Kai Shi, Yoichi Tatsumi, Oestergaard, Mikkel Z., Wenger, Michael, Fingerle-Rowson, Günter, Catalani, Olivier, Nielsen, Tina, and Martelli, Maurizio

Published
2017
Full Text
View/download PDF

4. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

Author

Kovacs, Gabor, Robrecht, Sandra, Fink, Anna Maria, Bahlo, Jasmin, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Langerbeins, Petra, Fingerle-Rowson, Günter, Ritgen, Matthias, Kneb, Michael, Döhner, Hartmut, Stilgenbauer, Stephan, Klapper, Wolfram, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara, Böttcher, Sebastian, and Kneba, Michael

Published
2016
Full Text
View/download PDF

5. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

Author

Sehn, Laurie H., Goy, Andre, Offner, Fritz C., Martinelli, Giovanni, Caballero, M. Dolores, Gadeberg, Ole, Baetz, Tara, Zelenetz, Andrew D., Gaidano, Gianluca, Fayad, Luis E., Buckstein, Rena, Friedberg, Jonathan W., Crump, Michael, Jaksic, Branimir, Zinzani, Pier Luigi, Padmanabhan Iyer, Swaminathan, Sahin, Deniz, Chai, Akiko, Fingerle-Rowson, Günter, and Press, Oliver W.

Published
2015
Full Text
View/download PDF

6. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Author

Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, and Kneba M

Subjects
Antibodies, Monoclonal, Murine-Derived administration & dosage, Cyclophosphamide administration & dosage, Disease Progression, Flow Cytometry, Humans, Neoplasm, Residual diagnosis, Prognosis, Prospective Studies, Rituximab, Survival Rate, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Neoplasm, Residual drug therapy, Neoplasm, Residual mortality
Abstract

Purpose: To determine the clinical significance of flow cytometric minimal residual disease (MRD) quantification in chronic lymphocytic leukemia (CLL) in addition to pretherapeutic risk factors and to compare the prognostic impact of MRD between the arms of the German CLL Study Group CLL8 trial., Patients and Methods: MRD levels were prospectively quantified in 1,775 blood and bone marrow samples from 493 patients randomly assigned to receive fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR). Patients were categorized by MRD into low- (< 10(-4)), intermediate- (≥ 10(-4) to <10(-2)), and high-level (≥ 10(-2)) groups., Results: Low MRD levels during and after therapy were associated with longer progression-free survival (PFS) and overall survival (OS; P < .0001). Median PFS is estimated at 68.7, 40.5, and 15.4 months for low, intermediate, and high MRD levels, respectively, when assessed 2 months after therapy. Compared with patients with low MRD, greater risks of disease progression were associated with intermediate and high MRD levels (hazard ratios, 2.49 and 14.7, respectively; both P < .0001). Median OS was 48.4 months in patients with high MRD and was not reached for lower MRD levels. MRD remained predictive for OS and PFS in multivariate analyses that included the most important pretherapeutic risk markers in CLL. PFS and OS did not differ between treatment arms within each MRD category. However, FCR induced low MRD levels more frequently than FC., Conclusion: MRD levels independently predict OS and PFS in CLL. Therefore, MRD quantification might serve as a surrogate marker to assess treatment efficacy in randomized trials before clinical end points can be evaluated.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results